Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The use of cannabis by patients with sickle cell disease increased the frequency of hospitalization due to vaso-occlusive crises
source: Cannabis and Cannabinoid Research
year: 2017
authors: Samir K. Ballas
summary/abstract:Introduction:
The objective of this study was to determine if patients with sickle cell disease using cannabis had decreased frequency of acute vaso-occlusive crises (VOCs) that required hospitalization.
Method:
This was a retrospective study in which 270 urine drug screen tests were done on 72 patients: 40 males and 32 females.
Results:
Cannabinoids were found in 144 urine tests from 37 patients and were negative in 126 tests from 35 patients. Males who used cannabis were significantly younger (p<0.001) than males who did not. Patients who tested positive used benzodiazepines, cocaine, and phencyclidine significantly more often than patients who tested negative. There was no significant difference in the amounts of opioids consumed by users and nonusers of cannabis. The cannabis cohort was seen in the clinic significantly (p<0.05) less often than controls, but hospital admissions were significantly greater in the cannabis group than controls (p<0.05).
Conclusion:
These data show an unexpected negative effect of cannabis on the frequency of VOCs. This may be due to the effect of cannabis on the brain and/or the severity of the disease in the cannabis users. More controlled studies are needed to clarify these findings.
DOI: 10.1089/can.2017.0011
read more
+myBinderRelated Content
-
Marijuana Use and Health Behaviors in a US Clinic Sample of Patients With Sickle Cell DiseaseIntroduction: As marijuana use becomes ...
-
Gut Microbiome Translates Stress Into Sickle Cell CrisesA new study shows how chronic psychologi...
-
Outcomes of an Emergency Department Observation Unit–Based Pathway for the Treatment of Uncomplicated Vaso-Occlusi...Study objective: This was a prospective...
-
CTX001 Continues to Show Promise in Severe SCDA single dose of CTX001, an experimental...
-
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
Research Team Recognized for Organ-on-a-Chip DesignSCD is a group of genetic disorders that...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.